The DOI matches its Crossref record; 317 of the 333 references it cites were found in a registry or an index.
Frontotemporal lobar degeneration
Open accessAbstract
Frontotemporal lobar degeneration (FTLD) is one of the most common causes of early-onset dementia and presents with early social-emotional-behavioural and/or language changes that can be accompanied by a pyramidal or extrapyramidal motor disorder. About 20-25% of individuals with FTLD are estimated to carry a mutation associated with a specific FTLD pathology. The discovery of these mutations has led to important advances in potentially disease-modifying treatments that aim to slow progression or delay disease onset and has improved understanding of brain functioning. In both mutation carriers and those with sporadic disease, the most common underlying diagnoses are linked to neuronal and glial inclusions containing tau (FTLD-tau) or TDP-43 (FTLD-TDP), although 5-10% of patients may have inclusions containing proteins from the FUS-Ewing sarcoma-TAF15 family (FTLD-FET). Biomarkers definitively identifying specific pathological entities in sporadic disease have been elusive, which has impeded development of disease-modifying treatments. Nevertheless, disease-monitoring biofluid and imaging biomarkers are becoming increasingly sophisticated and are likely to serve as useful measures of treatment response during trials of disease-modifying treatments. Symptomatic trials using novel approaches such as transcranial direct current stimulation are also beginning to show promise.
Overview
CoChat Summary
TL;DR
Frontotemporal lobar degeneration (FTLD) is described as a major cause of early-onset dementia with early behavioral, language, and sometimes motor changes. This review highlights that about 20–25% of cases carry a pathogenic mutation, while biomarker and treatment development remain challenging but are advancing.
Key findings
- FTLD is “one of the most common causes of early-onset dementia” and presents with early social-emotional-behavioural and/or language changes, sometimes with pyramidal or extrapyramidal motor disorder.
- About 20–25% of individuals with FTLD are estimated to carry a mutation associated with a specific FTLD pathology.
- The most common underlying pathological diagnoses are FTLD-tau and FTLD-TDP; about 5–10% of patients may have FTLD-FET.
- The paper states that biomarker identification of specific pathology in sporadic disease has been elusive, but biofluid and imaging biomarkers are becoming more sophisticated and may help monitor treatment response; symptomatic trials such as transcranial direct current stimulation are “beginning to show promise.”
Methods
- Review article (Nature Reviews Disease Primers) synthesizing the FTLD literature; no original study design is stated.
- No sample, cohort, or dataset is described in the provided text.
- Main analysis is narrative review and expert synthesis of disease presentation, genetics, pathology, biomarkers, and emerging therapies.
Limitations
- The text states that biomarkers definitively identifying specific pathological entities in sporadic disease have been elusive, which has impeded development of disease-modifying treatments.
- No formal study limitations are stated in the paper text provided.
- As a review, it does not present original primary data or a new cohort for direct inference (evident from the text).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 0 Not valid · 0 Not checked · 8 Own results and interpretations
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and are likely to serve as useful measures of treatment response during trials of disease-modifying treatments.”
- Also stated in: § Abstract · hedged
“are likely to serve as useful measures of treatment response during trials of disease-modifying treatments”
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
- Also stated in: § Abstract · hedged
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Biomarkers definitively identifying specific pathological entities in sporadic disease have been elusive”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
- Rests on 2 assumptions not shown here.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The discovery of these mutations has led to important advances in potentially disease-modifying treatments”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“which has impeded development of disease-modifying treatments”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Probably not a substantial claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Neurological symptoms including blindness, deafness, seizures, and cognitive and motor decline, as well as non-CNS involvement with pulmonary, GI, cardiac, hematological, and bone manifestations.65”
From The lysosome and proteostatic stress at the intersection of pediatric neurological disorders and adult neurodegenerative diseases (2025) · cites this paper as [65]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“LSDs are a set of disorders with heterogenous phenotypes.”
From The lysosome and proteostatic stress at the intersection of pediatric neurological disorders and adult neurodegenerative diseases (2025) · cites this paper as [65]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Most lysosomal storage disorders have classic autosomal recessive inheritance, thus allowing for precise identification of the causative gene in affected families.65”
From The lysosome and proteostatic stress at the intersection of pediatric neurological disorders and adult neurodegenerative diseases (2025) · cites this paper as [65]
Experimental — accuracy not yet measured
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G. P., Onyike, C. U., et al. (2011) · Brain · doi:10.1093/brain/awr179 · Cited by 5,221
Self-citationClassification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141
Self-citationDeJesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., Boxer, A. L., Baker, M., Rutherford, N. J., Nicholson, A. M., Finch, N. A., Flynn, H., Adamson, J., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.011 · Cited by 4,936
Self-citationA Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD
Renton, A. E., Majounie, E., Waite, A., Simón-Sánchez, J., Rollinson, S., Gibbs, J. R., Schymick, J. C., Laaksovirta, H., van Swieten, J. C., Myllykangas, L., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.010 · Cited by 4,409
Greicius, M. D., Srivastava, G., Reiss, A. L., & Menon, V. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308627101 · Cited by 3,684
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Appelhof, B., Bakker, C., Van Duinen-van den Ijssel, J. C. L., Zwijsen, S. A., Smalbrugge, M., Verhey, F. R. J., de Vugt, M. E., Zuidema, S. U., & Koopmans, R. T. C. M. (2017) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000477087 · Cited by 2,760
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
Höglinger, G. U., Respondek, G., Stamelou, M., Kurz, C., Josephs, K. A., Lang, A. E., Mollenhauer, B., Müller, U., Nilsson, C., Whitwell, J. L., et al. (2017) · Movement Disorders · doi:10.1002/mds.26987 · Cited by 2,359
Self-citationNeurodegenerative Diseases Target Large-Scale Human Brain Networks
Seeley, W. W., Crawford, R. K., Zhou, J., Miller, B. L., & Greicius, M. D. (2009) · Neuron · doi:10.1016/j.neuron.2009.03.024 · Cited by 2,350
Self-citation
Research works printed but not linked: 2
- Logsdon, R. G., Gibbons, L., McCurry, S. M. & Teri, L. Quality of life in Alzheimer’s disease: patient and caregiver reports. J. Ment. Health Aging 5, 21–32 (1999).
- Deleon, J. & Miller, B. L. in Neurogenetics, Part II (eds Geschwind, D. H., Paulson, H. L. & Klein, C.) 409–430 (Elsevier, 2018). [Series Eds Aminoff, M. J., Boller, F. & Swaab, D. F. Handbook of Clinical Neurology Vol. 148].
Cited by
Neurofilaments as biomarkers in neurological disorders — towards clinical application
Khalil, M., Teunissen, C. E., Lehmann, S., Otto, M., Piehl, F., Ziemssen, T., Bittner, S., Sormani, M. P., Gattringer, T., Abu-Rumeileh, S., et al. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00955-x · Cited by 446
“Approximately 30% of cases are familial, caused by mutations in MAPT (tau pathology), C9Orf72 (TDP43 pathology) or GRN (TDP43 pathology) 153 .”
Self-citationDementia Prevention and Treatment: A Narrative Review
Reuben, D. B., Kremen, S., & Maust, D. T. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.8522 · Cited by 202
Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances
Jiang, Q., Liu, J., Huang, S., Wang, X.-Y., Chen, X., Liu, G.-H., Ye, K., Song, W., Masters, C. L., Wang, J., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02145-7 · Cited by 165
“94 Although ALS and FTLD have different disease manifestations, many genetic and pathological mechanisms overlap.”
Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies
Zhang, X., Wang, J., Zhang, Z., & Ye, K. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00429-6 · Cited by 125
“CTE is characterized by clusters of twisted neurofibrillary tangles (NFTs) composed of both 3R and 4R tau, noticeable tangled fibers within the neuropil, and astroglial tau pathology [15].”
BackgroundThe Enigma of Tau Protein Aggregation: Mechanistic Insights and Future Challenges
Zheng, H., Sun, H., Cai, Q., & Tai, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094969 · Cited by 76
Metadata
- Authors
- Grossman, M., Seeley, W. W., Boxer, A. L., Hillis, A. E., Knopman, D. S., Ljubenov, P. A., Miller, B., Piguet, O., Rademakers, R., Whitwell, J. L., Zetterberg, H., & van Swieten, J. C.
- Affiliations
- University of Pennsylvania (US)
- University of California, San Francisco (US)
- Johns Hopkins University (US)
- Mayo Clinic (US)
- The University of Sydney (AU)
- University of Antwerp (BE)
- University of Wisconsin–Madison (US)
- Corresponding author
- Seeley, William W.
- ORCID
- Venue
- Nature Reviews Disease Primers
- Published
- 2023-08-10
- Volume
- 9
- Issue
- 1
- Pages
- 40-40
- ISSN
- 2056-676X (ISSN-L)
- OpenAlex
- W4385721201
- Cited by
- 178
- References
- 333
- Citations by year
- 2026: 62 · 2025: 61 · 2024: 49 · 2023: 6
- FWCI
- 8.15
- Type
- journal article
- Language
- en
- Open access
- green
- pure.eur.nl
- Licence
- other-oa
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Reviews Disease Primers (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Eli Lilly and Company
- Biogen
- Regeneron Pharmaceuticals
- University of Cambridge
- European Commission (101,053,962, ALFGBG-71320)
- Eisai
- Vetenskapsrådet (#101053962, 2022-01018, ALFGBG‐71320, 2019-02397)
- National Institutes of Health (AG066597)
- HORIZON EUROPE Framework Programme (101053962)
- Medical Research Council
- National Health and Medical Research Council (2008020)
- National Institute on Aging (AG066597)
- National Institute on Deafness and Other Communication Disorders (R01DC014942, R01DC012519)
- National Institute of Neurological Disorders and Stroke (RF1NS112153, R01NS089757)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- frontotemporal lobar degeneration, early-onset dementia, FTLD-tau, FTLD-TDP, tau inclusions, TDP-43 inclusions, genetic mutations, disease-modifying therapy, biomarkers, biofluid biomarkers, neuroimaging biomarkers, transcranial direct current stimulation, motor disorders
- MeSH terms
- Humans, Biomarkers, Frontotemporal Lobar Degeneration, Frontotemporal Dementia, Transcranial Direct Current Stimulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Frontotemporal lobar degeneration. https://app.cochat.ai/papers/10.1038/s41572-023-00447-0
- The paper
- Grossman, M., Seeley, W. W., Boxer, A. L., Hillis, A. E., Knopman, D. S., Ljubenov, P. A., Miller, B., Piguet, O., Rademakers, R., Whitwell, J. L., Zetterberg, H., & van Swieten, J. C. (2023). Frontotemporal lobar degeneration. Nature Reviews Disease Primers. https://doi.org/10.1038/s41572-023-00447-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.